Adcytherix Secures €105M Series A to Advance Cancer Drug Pipeline
Adcytherix SAS, a French biopharmaceutical company developing next-generation antibody drug conjugates (ADCs), has closed a €105 million (US$122 million) Series A funding round — the…
Read More...
Read More...
